2010
GHS-R1a Receptor Binding
Howard et al.
Characterized ipamorelin and analogues as selective ghrelin-receptor agonists.
Lot CBR-IPA-260411-001✓ Verified
About Ipamorelin
Ipamorelin is a synthetic pentapeptide growth-hormone-releasing peptide (GHRP) developed at Novo Nordisk in the late 1990s. It is characterized in the literature as a selective GH secretagogue with limited ACTH, cortisol, and prolactin response reported in pre-clinical models.
Research interest centers on the ghrelin-receptor (GHS-R1a) axis and selective GH-pulse studies. The peptide has been investigated in models of growth-hormone insufficiency, post-operative recovery research, and metabolic studies.
Each lot is independently verified for purity (HPLC + ESI-MS) and endotoxin (LAL kinetic chromogenic) before listing.
Identity & Specifications
Sequence
Aib-His-D-2Nal-D-Phe-Lys-NH₂
Length
5 residues
Formula
C₃₈H₄₉N₉O₅
Mol. weight
711.86 g/mol
CAS
170851-70-4
PubChem
11378266
Purity (HPLC)
≥ 98%
Endotoxin (LAL)
< 0.5 EU/mg
Certificate of Analysis
Lot CBR-IPA-260411-001 — purity and potency independently verified by BTLabs (West Palm Beach, FL); bacterial endotoxin independently verified by Freedom Diagnostics (Franklin, TN). Full parameter results below.
| Parameter | Method | Spec | Result |
|---|---|---|---|
| Identity | FTIR (USP <197A>) | Confirms Ipamorelin | Conforms |
| Appearance | Visual (USP <630>) | White powder | White powder |
| Purity | HPLC-UV 280 nm (USP <621>) | ≥ 98.0% | 99.8% |
| Potency | HPLC-UV 280 nm (USP <621>) | 90 – 110% of 10 mg | 10.8 mg (107.9%) |
| Endotoxin | LAL (USP <85>) | ≤ 0.05 EU/mL | Pass |
Signed Certificate of Analysis
Independent third-party laboratories: BTLabs · 5730 Corporate Way, Suite 220, West Palm Beach, FL 33407 · (561) 625-0133 and Freedom Diagnostics · Franklin, TN. Three signed pages reproduced below verbatim. Open the original PDF →
Selected References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
- Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 1996.
- Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid effects on bone formation. Horm Res, 2002.
- Pradhananga S, et al. Ghrelin receptor agonist promotes recovery in post-operative ileus. Neurogastroenterol Motil, 2015.
- Smith RG, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev, 1997.
Recent Research Highlights
1998
Original Characterization
Raun et al. · Eur J Endocrinol
Original report describing ipamorelin as a selective GH secretagogue with low effects on stress-axis markers.
2003
Bone Formation Models
Andersen et al.
Examined effects on bone-mass markers in GH-deficient rodent models.
2008
Post-operative Recovery
Greenwood-Van Meerveld et al.
Investigated GHRP analogues in models of post-operative gastrointestinal recovery.
⊕
3rd Party Tested
Independent lab
≥98%
HPLC Purity
+ ESI-MS
LAL
Endotoxin
LAL kinetic
§
Lot-traceable
In COA library
§ Research-Use Compliance
Laboratory research chemical / reagent — not a supplement or drug.
This compound is supplied by Crescent Bioresearch LLC for laboratory research and pre-clinical use only. It is not a drug, dietary supplement, food, or cosmetic, and has not been approved by the U.S. Food and Drug Administration for human or veterinary administration, diagnosis, treatment, or prevention of any condition.
The pharmacological, toxicological, and stability properties of this compound have not been fully studied. It must therefore be handled only by personnel trained in laboratory safety practices.
The purchaser bears sole responsibility for ensuring that all handling, storage, and intended use comply with applicable local, state, and federal regulations. Full terms are set out in the RUO Disclaimer and Terms of Service.
